A single amino acid change in Ras eliminates its ability to hydrolyze GTP, even in the presence of a GTPase-activating protein (GAP). Roughly 30% of human cancers have this change in Ras. You have just identified a small molecule that prevents the dimerization of a receptor tyrosine kinase that signals via Ras. Would you expect this molecule to be effective in the treatment of cancers that express wild type or mutant form of Ras

Generally ligand binds to RTK——————— > RTK dimer formation————— > autophosphorylation occurs in RTK—————— > RTK activation—————— > This RTK activates RAS—————- > which activates many cellular processes————- > cancer.

Already, it nanoparticle stops RTK dimerization. As a result, RTK will not be triggered but the above-described sequence of activities would not be able to happen (from bold above); therefore, cancer can be precluded.